ClinicalTrials.gg
Not yet recruitingNCT07869797Updated Oct 13, 2026

Real-world Study of the Effectiveness and Tolerability of Outpatient Titration of OxyContin for the Moderate and Severe Pain in Cancer Patients

An observational study in Cancer Pain, sponsored by Mundipharma (China) Pharmaceutical Co. Ltd. Not yet recruiting at 20 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Mundipharma (China) Pharmaceutical Co. Ltd (part of Mundipharma) · Observational

Updated Oct 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
378
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 11 studies in Cancer Pain by Mundipharma — 1 open to participants now, 1 under way, none of them phase 3. Cancer Pain · Mundipharma.

Started
2026
the only one that year
Observational
2 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Cancer Pain by Mundipharma, this one is the only one that started in 2026, is one of 2 observational ones, and was the 11th registered.

Cancer Pain

311 studies on the registry are indexed under Cancer Pain; 74 are open to participants now.

Browse Cancer Pain studies →

Open to participants now

1 of the 11 studies in Cancer Pain by Mundipharma is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 45 Cancer Pain studies recruiting now, 33 (73%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Cancer Pain by Mundipharma, or all of them as a file.
02

Study summary

The purpose of this observational study is to evaluate the effectiveness and tolerability of outpatient titration regimen with OxyContin as background for moderate and severe pain in cancer patients in adult patients with moderate to severe cancer pain. The main questions it aims to answer are

  • To evaluate the effectiveness of titration regimen with OxyContin as background for the moderate and severe pain in cancer participants
  • To explore the tolerability of titration regimen with OxyContin as background use in outpatient participants with moderate and severe cancer pain
Read the detailed description

Primary Endpoints: The proportion of participants achieving pain remission, which is defined as the rate of participants with average NRS (Numerical rating scale) score ≤3 [CR (Complete remission)] or achieving a reduction of 25% when NRS score >3 [PR (Partial remission)] at 72 h.

Secondary Endpoints:

  • The proportions of participants with CR and PR at 24h and 48h
  • Time-to-first CR and PR
  • The respective proportions of participants with no rescue medication use at 24h, 48h, and 72h
  • Pain severity subscale score, interference of pain subscale score from the BPI-SF
  • The average titration dosage of OxyContin
  • The average maintenance dosage of OxyContin
  • Adverse events: the frequency and severity of adverse event
03

Conditions studied

  • Cancer Pain

Keywords

  • moderate and severe pain in cancer patients
  • outpatient titration of OxyContin
  • Real-world study
  • effectiveness and tolerability
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with moderate-to-severe cancer pain treated with the outpatient OxyContin dose titration regimen,able to complete questionnaire and scale assessments.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female cancer participants, age ≥ 18 years
  • Participants presenting with moderate to severe (NRS ≥ 4 points) cancer-related pain
  • Participants undergoing outpatient titration regimen with OxyContin as background, see Appendix 3
  • Voluntarily sign an form

Exclusion criteria

Exclusion Criteria:

  • Participants with cognitive impairment, delirium, psychiatric disorders, or other conditions that may interfere with reliable pain self-assessment
  • Participants are receiving surgery or minimally invasive interventional pain management
  • Participants are not willing to cooperate in completing follow-up
  • The investigator judges as unsuitable for inclusion in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
378 participants (estimated)
Target follow-up
8 Days
Patient registry
Yes

Groups and cohorts

  • Outpatient OxyContin Dose Titration for Patients with Moderate-to-Severe Cancer Pain

    Outpatient OxyContin Dose Titration for Patients with Moderate-to-Severe Cancer Pain,This study is a multi-center prospective single arm real-world study with OxyContin as background titration. The study consists of 2 phases: Screening/ titration phase and maintenance phase.

06

What researchers measure

Primary outcomes

  1. The proportion of participants achieving pain relief after treatment.

    Pain assessments will be performed using the BPI-SF (Brief Pain Inventory-Short Form) and NRS (Numerical Rating Scale). The proportion of participants achieving pain remission, which is defined as the rate of participants with average NRS (Numerical rating scale) score ≤3 \[CR (Complete remission)\] or achieving a reduction of 25% when NRS score \>3 \[PR (Partial remission)\] at 72 h

    Time frame: From enrollment to the end of follow-up at Day 8.

Secondary outcomes

  1. Adverse events: the frequency and severity of adverse events

    assessed primarily by adverse events occurring after treatment (defined as adverse events that emerge or worsen following the first dose of OxyContin), and may also be evaluated via physical examinations and vital signs.

    Time frame: From enrollment to the end of follow-up at Day 8.

07

Study locations

20 sites
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared with other researchers, due to privacy protection and ethical considerations. Study results may be published in the form of aggregated summary data.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Apr 2027, 6 months later.

Of 26 observational studies under Cancer Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 40. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 13, 2026
StartEst.
Oct 2026
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07869797
Collaborators
Tigermed Consulting Co., Ltd
Responsible party
Sponsor
First posted
Oct 13, 2026
Start date
Oct 2026 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Gang Peng
Contact
Gang.Peng@mundipharma.com.cn
+86 13699158703
Xu Chen
Contact
xu.chen@tigermedgrp.com
+86 18019947155
Minghua Cong, MD
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion